Edition:
United States

Addex Therapeutics Ltd (ADXN.S)

ADXN.S on Swiss Exchange

2.17CHF
18 Aug 2017
Change (% chg)

CHF-0.05 (-2.25%)
Prev Close
CHF2.22
Open
CHF2.22
Day's High
CHF2.22
Day's Low
CHF2.17
Volume
30,037
Avg. Vol
17,360
52-wk High
CHF3.10
52-wk Low
CHF1.70

Latest Key Developments (Source: Significant Developments)

Addex Therapeutics says data indicates ADX71441 may be beneficial in treating alcohol use disorder
Thursday, 4 May 2017 01:00am EDT 

May 4 (Reuters) - Addex Therapeutics Ltd :Addex ADX71441 preclinical results for treatment of alcohol use disorder published in journal of psychopharmacology.Data indicated that ADX71441 may be beneficial in treating alcohol use disorder in humans.expect to initiate a phase i study for ADX71441 as a potential treatment for alcohol and cocaine addiction in Q3 of this year.  Full Article

Addex Therapeutics FY2016 net loss shrinks to CHF 3.1 mln
Wednesday, 5 Apr 2017 01:00am EDT 

Addex Therapeutics Ltd : FY net loss for the year decreased significantly to 3.1 million Swiss francs ($3.09 million)for 2016, compared to 4.2 million Swiss francs for 2015 .Cash and cash equivalents decreased by 46% to 1.4 million francs at Dec. 31, 2016, compared to 2.6 million francs at Dec. 31, 2015.  Full Article

Addex Therapeutics FY cash and cash equivalents of CHF 1.4 mln
Tuesday, 28 Feb 2017 01:01am EST 

Addex Therapeutics Ltd : Raises 3.0 million Swiss francs ($2.98 million) through private placement of treasury shares and extends cash runway through 2018 . It has raised gross proceeds of 3.0 million Swiss francs through a private placement in which 1.5 million treasury shares were placed at 2 francs per share .Addex completed 2016 with cash and cash equivalents of 1.4 million Swiss francs (2015: 2.6 million Swiss francs).  Full Article

Addex Therapeutics H1 net loss shrinks to CHF 1.5 million
Friday, 30 Sep 2016 01:00am EDT 

Addex Therapeutics Ltd : H1 net loss 1.485 million Swiss francs ($1.54 million) versus loss 2.833 million francs year ago . H1 income 283,000 francs versus 90,000 francs year ago .Research and Development expenses increased to 1.1 million francs in H1 of 2016 compared to 0.9 million francs in H1 of 2015.  Full Article

Addex Therapeutics publishes data on phase II trial with Dipraglurant in specialist magazine
Thursday, 2 Jun 2016 01:00am EDT 

Addex Therapeutics Ltd : Results from its phase 2 clinical study of dipraglurant in levodopa-induced dyskinesia associated with Parkinson's disease have been published in online issue of peer-reviewed journal movement disorders .Results show that there were no major safety concerns in trial.  Full Article

Addex Therapeutics increases share capital
Monday, 30 May 2016 01:05am EDT 

Addex Therapeutics Ltd : Has increased its capital from 11,699,612 to 13,454,553 through the issue of 1,754,941 new registered shares at nominal value of 1 Swiss franc ($1.01) each to Addex Pharma S.A, its 100 pct subsidiary .Executed this transaction to provide additional financing flexibility as we execute on our strategy to advance the clinical development of dipraglurant and ADX71441.  Full Article

Addex Therapeutics reports positive results of an mGlu5 receptor occupancy study
Monday, 11 Apr 2016 01:00am EDT 

Addex Therapeutics:Reports positive results of an mGlu5 receptor occupancy study.  Full Article

Addex Therapeutics completes mGlu5 receptor occupancy study with dipraglurant in healthy volunteers
Tuesday, 15 Mar 2016 02:01am EDT 

Addex Therapeutics:Reports successful completion of an mGlu5 receptor occupancy study with dipraglurant in healthy volunteers.  Full Article

Addex Therapeutics announces positive data on dipraglurant in Parkinson's treatment
Monday, 11 Jan 2016 01:00am EST 

Addex Therapeutics:Addex dipraglurant shows highly statistically significant anti-dyskinetic effects following additional analysis of data from the PD-lid phase II proof of concept.Additional analysis underlines potential significant therapeutic benefit of dipraglurant to patients with Parkinson's disease.  Full Article

Addex Therapeutics FDA grants orphan drug designation to dipraglurant
Monday, 4 Jan 2016 01:01am EST 

Addex Therapeutics:Addex' dipraglurant receives orphan drug designation from FDA for levodopa-induced dyskinesia associated with Parkinson's disease​.  Full Article

BRIEF-Addex Therapeutics FY2016 net loss shrinks to CHF 3.1 mln

* FY net loss for the year decreased significantly to 3.1 million Swiss francs ($3.09 million)for 2016, compared to 4.2 million Swiss francs for 2015